SCHEMBL30830550

SCHEMBL30830550

CN1C[C@H](Nc2cnn(C)c(=O)c2Br)C[C@H](c2ccc(C(=O)N3CC4(C3)CN(c3cccc(C5CCC(=O)NC5=O)c3)C4)cc2)C1

nearest known ligand 0.52

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ KAT2B Q92831 14/20 0.52
▸ BRD9 Q9H8M2 3/20 0.52
▸ BPTF Q12830 2/20 0.52
▸ KAT2A Q92830 2/20 0.52
▸ BRD1 O95696 1/20 0.52
▸ ACHE P22303 1/20 0.52
▸ BRPF1 P55201 1/20 0.52
▸ BRD7 Q9NPI1 1/20 0.52
▸ BAZ2B Q9UIF8 1/20 0.52
▸ BRPF3 Q9ULD4 1/20 0.52
▸ DDB1 Q16531 4/20 0.32
▸ CRBN Q96SW2 4/20 0.32
▸ SETDB1 Q15047 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30830792 0.94 KAT2B (0.51) KAT2BBRD9BPTFKAT2ABRD1
SCHEMBL30831027 0.93 KAT2B (0.52) KAT2BBRD9BPTFKAT2ABRD1
SCHEMBL30830721 0.91 KAT2B (0.51) KAT2BBRD9BPTFKAT2ABRD1
SCHEMBL30830823 0.90 KAT2B (0.58) KAT2BBRD9BPTFKAT2ABRD1
SCHEMBL30830947 0.88 KAT2B (0.53) KAT2BBRD9BPTFKAT2ABRD1
SCHEMBL30830967 0.87 KAT2B (0.50) KAT2BBRD9BPTFKAT2ABRD1
SCHEMBL30830519 0.87 KAT2B (0.50) KAT2BBRD9BPTFKAT2ABRD1
SCHEMBL30830595 0.87 KAT2B (0.50) KAT2BBRD9BPTFKAT2ABRD1
SCHEMBL30830680 0.86 KAT2B (0.54) KAT2BBRD9BPTFKAT2ABRD1
SCHEMBL30830768 0.86 KAT2B (0.58) KAT2BBRD9BPTFKAT2ABRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4581025-A1 PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS Auron Therapeutics, Inc. (US) 2025-07-09 — — EP disclosed
WO-2024050078-A1 PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS AURON THERAPEUTICS, INC. (US) 2024-03-07 — — WO disclosed
Send feedback